KKKyoichi Kaira

Kyoichi Kaira

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Kyoichi Kaira has a total of 80 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

    • 9 June 2016
      • Vol. 21  (2) , 333-40

    Comparison of the efficacy of radiotherapy between postoperative mediastinal lymph node recurrence and stage III disease in non-small cell lung cancer patients.

    by Hisao Imai, Haruyasu Murakami, Reiko Yoshino, Keita Mori, Kiyomi Sumita, Akira Ono, Hiroaki Akamatsu, Tetsuhiko Taira, Hirotsugu Kenmotsu, Hideyuki Harada, et al.

    It is unknown if local treatment is equally effective in non-small cell lung cancer (NSCLC) patients with postoperative mediastinal lymph node recurrence or primary stage III disease. The purpose of this study was to investigate the effectiveness of radiotherapy, with or without chemotherapy, in patients with postoperative mediastinal lymph node recurrence. Patient characteristics, treatment response and survival were compared between NSCLC patients with mediastinal lymph node metastases treated between 2002-2009 by radiotherapy alone or by chemoradiotherapy (group A, N=33) and those with primary stage III disease (group B, N = 157). Men accounted for 60.6% of group A and 78.9% of group B (p=0.04 patients). ECOG performance status 0 was detected in 78.7% of group A and 57.3% of group B (p=0.02). The response rates in groups A and B were 66.6 and 72.3%, respectively (p=0.64). Progression-free survival (PFS) was similar between groups A and B (median 15.0 vs 11.0 months; hazard ratio [HR] 0.78; 95% CI 0.51-1.20; p=0.26). However, overall survival (OS) was better in group A than in group B (median 67.0 vs 39.0 months; HR 0.56; 95% CI 0.29-0.97; p=0.03). Postoperative PFS (median 12.5 vs 19.0 months; HR 1.50; 95% CI 0.64-3.49; p=0.34) and OS (median, 67.0 vs 60.0 months; HR 1.22; 95% CI 0.36-4.14; p=0.74) were similar between the group A treatments (radiotherapy and chemoradiotherapy, respectively). Postoperative mediastinal lymph node recurrent NSCLC demonstrated distinctive features including better OS compared to patients with primary stage III disease, despite similar response rates and PFS.


  • Comparison of platinum rechallenge and docetaxel in non-small cell lung cancer previously treated with chemoradiotherapy

    by Hisao Imai, Kyoichi Kaira, Akira Ono, Hiroaki Akamatsu, Tetsuhiko Taira, Reiko Yoshino, Hirotsugu Kenmotsu, Tateaki Naito, Haruyasu Murakami, Toshiaki Takahashi

    • 1 August 2013
      • Vol. 33  (8) , 3279-84

    Comparison of the time-to-response between radiotherapy and epidermal growth factor receptor--tyrosine kinase inhibitors for advanced non-small cell lung cancer with EGFR mutation.

    by Hisao Imai, Takehito Shukuya, Toshiaki Takahashi, Sakae Fujiwara, Keita Mori, Akira Ono, Hiroaki Akamatsu, Tetsuhiko Taira, Hirotsugu Kenmotsu, Tateaki Naito, et al.

    Patients harboring sensitive epidermal growth factor receptor (EGFR) mutations show a dramatic response to treatment with EGFR tyrosine kinase inhibitors (TKIs). However, there have been no clinical reports in lung cancer patients that compare the time-to-response between radiotherapy and EGFR-TKIs. We reviewed 17 and 32 consecutive patients with inoperable stage III/IV NSCLC who harbored sensitive EGFR mutations and who were treated with thoracic radiotherapy with or without chemotherapy and EGFR-TKIs, respectively. There were statistically significant differences in time-to-partial response (PR) with regard to the treatment modalities (radiotherapy vs. EGFR-TKIs, median 57 days vs. 22 days, log-rank test, p=0.008). EGFR-TKIs elicit tumor shrinkage earlier than does radiotherapy in patients with a sensitive EGFR mutation, suggesting that EGFR-TKIs may be useful for early symptom improvement in these patients.


  • Open Access

    Correlation between computed tomography findings and epidermal growth factor receptor and Kras gene mutations in patients with pulmonary adenocarcinoma

    by Kimihiro Shimizu, Masayuki Sugano, Tetsuhiro Nakano, Seiichi Kakegawa, Yohei Miyamae, Kyoichi Kaira, Takuya Araki, Mitsuhiro Kamiyoshihara, Osamu Kawashima, Izumi Takeyoshi

    We examined the correlation between computed tomography (CT) findings and the incidence of epidermal growth factor receptor (EGFR) and KRAS mutations in lung adenocarcinoma. We analyzed the tumors of 136 patients with surgically resected primary lung adenocarcinoma. CT scans were evaluated for the presence of ground grass opacity (GGO), spiculation and the maximum diameter of the tumor was measured. SMart Amplification Process (ver. 2) was used to detect the presence of EGFR and KRAS mutations. EGFR and KRAS mutations were found in 56 (41.1%) and 25 (18.4%) of the 136 cases, respectively. Although no significant association was found between GGO and EGFR mutations (p=0.07), the EGFR mutation occurred more frequently in male patients with GGO than in those without GGO (p=0.04). The KRAS mutation occurred more frequently in patients whose tumor diameter was ≥ 31 mm than in those whose tumor diameter was <30 mm (p=0.003). Evaluation of CT findings may be helpful for determining the presence of EGFR and KRAS mutations, particularly when it is not possible to obtain a tumor specimen.


  • A Case of Paragonimiasis Miyazakii with Various Chest Shadows on CT

    by Hisao Imai, Norio Horiguchi, Yasuki Iwasaki, Tamon Nagashima, Hiroaki Tsurumaki, Kunio Yanagisawa, Shinsuke Ohi, Kyoichi Kaira, Akihiro Ono, Yasuhiko Koga, et al.

    • 1 December 2010
      • Vol. 30  (12) , 4819-28

    Inhibition of L-type amino acid transporter 1 has antitumor activity in non-small cell lung cancer.

    by Hisao Imai, Kyoichi Kaira, Noboru Oriuchi, Kimihiro Shimizu, Hideyuki Tominaga, Noriko Yanagitani, Noriaki Sunaga, Tamotsu Ishizuka, Shushi Nagamori, Kanyarat Promchan, et al.

    L-type amino acid transporter 1 (LAT1) is highly expressed in various human neoplasms. Antitumor activity of inhibiting LAT1 was analyzed in non-small cell lung cancer (NSCLC). Expression of LAT1 mRNA in 54 lung cancer cell lines was examined by RT-PCR. An inhibitor of LAT1, 2-aminobicyclo-(2,2,1)-heptane-2-carboxylic acid (BCH), was administered to H1395 cell. LAT1 expression was examined in correlation with clinical features and outcome in 51 NSCLC patients. Inhibition of LAT1 by BCH reduced cell viability in H1395 cells. Furthermore, co-administration of gefitinib with BCH reduced the viability of the cells more than either agent alone. Inhibition of LAT1 reduced the level of phosphorylation of mTOR, p70S6K and 4EBP1. LAT1 protein expression was closely associated with wild type EGFR, and was an independent significant factor to predict a poor prognosis. Inhibition of LAT1 may be a new rationale to the effective therapy of NSCLC without EGFR mutation.


    • 1 April 2009
      • Vol. 47  (4) , 286-90

    [A case of cryptogenic organizing pneumonia with eosinophilic infiltration which was difficult to distinguish from nonspecific interstitial pneumonia].

    by Noriko Yanagitani, Tamotsu Ishizuka, Mitsugu Hironaka, Kyoichi Kaira, Hisao Imai, Tadayoshi Kawata, Mitsuyoshi Utsugi, Yasuo Shimizu, Noriaki Sunaga, Takeshi Hisada, et al.

    A 57-year-old man presented with shortness of breath of four months duration which had recently become worse. A chest X-ray and computed tomography (CT) showed diffuse ground-glass opacities of the bilateral lower lungs suggesting interstitial pneumonia. The number of eosinophils was increased in the bronchoalveolar lavage fluid (BALF) (52%) and peripheral blood. A histological examination of the specimen obtained by TBLB revealed organized pneumonia with slight infiltration of inflammatory cell. Because the images were not typical of chronic eosinophilic pneumonia, video-assisted thoracic surgery biopsy was performed. The histological findings of the resected specimen showed organizing pneumonia with infiltration of eosinophils in the alveolar walls. He had not taken any medication prior to coming to the hospital and he was negative for medicine-related pneumonia. The oral administration of prednisolone (0.5 mg/kg) improved his symptoms and also CT findings.


    • 1 February 2009
      • Vol. 36  (2) , 299-300

    [Effective gemcitabine plus S-1 treatment in elderly non-small cell lung cancer patients with multiple bone metastases].

    by Kyoichi Kaira, Noriko Yanagitani, Noriaki Sunaga, Hisao Imai, Mitsuyoshi Utsugi, Tadayoshi Kawata, Takeshi Hisada, Kimihiro Shimizu, Tamotsu Ishizuka, Masatomo Mori

    An 81-year-old man presented with right shoulder pain 10 months after surgery for non-small cell lung cancer (p- T3N0M0, Stage II b). FDG-PET revealed an increased uptake in the multiple bone and mediastinal lymph nodes, suggestive of recurrence of lung cancer. He was given combined chemotherapy of gemcitabine plus S-1 as first-line treatment. This regimen was performed as a phase I trial for an elderly patient with advanced non-small cell lung cancer, and the treatment proved effective. No toxic events were observed due to this therapy, so he was treated as an outpatient for one year. He was considered to have good quality of life.

    • 1 September 2008
      • Vol. 35  (9) , 1587-9

    [A case of elderly non-small cell lung cancer effectively treated by combined chemotherapy of gemcitabine and S-1].

    by Kyoichi Kaira, Noriaki Sunaga, Noriko Yanagitani, Hisao Imai, Mitsuyoshi Utsugi, Yasuo Shimizu, Tadayoshi Kawata, Takeshi Hisada, Kimihiro Shimizu, Takafumi Tsuchiya, et al.

    The patient was an 86-year-old female who suffered from advanced non-small cell-lung cancer (cT4N3M1, Stage IV). She was treated with combined chemotherapy of gemcitabine and S-1 as first-line therapy. This regimen was performed as a phase I trial for elderly patients with advanced non-small cell lung cancer. The treatment assessment was evaluated as partial response. No toxic events were observed due to this therapy, so she was treated as an outpatient. She was considered to have good quality of life.

    • 1 September 2008
      • Vol. 35  (9) , 1619-21

    Pulmonary toxicity associated with vinorelbine-based chemotherapy in breast cancer.

    by Noriko Yanagitani, Yasuo Shimizu, Kyoichi Kaira, Sayaka Tatsuno, Noriaki Sunaga, Tamotsu Ishizuka, Masatomo Mori

    A 41-year-old woman had undergone a left mastectomy breast cancer three years prior to presentation. No for at six months she had recurrence, this time in the right breast and skin. Despite first-and second-line chemotherapy, the mass showed progression of the disease. Thereafter, a weekly treatment of vinorelbine and trastuzumab was started, but one month later, she developed a slight fever and dry cough. A chest CT scan revealed an infiltration shadow showing non-specific interstitial pattern in the right lung. A bronchoscopic examination showed lymphocyte dominance in bronchial lavage fluid, and lymphocyte infiltration into the interstium with fibrosis in the tissue specimens was found by transbronchial lung biopsy. After discontinuing the above vinorelbine therapy, the patient's condition improved. We therefore diagnosed this as a case of vinorelbine-and trastuzumab-induced interstitial pneumonia.